.

follow-on-google-news

Pharma stock engaged in the business of manufacturing, marketing, trading, and selling a wide range of pharmaceutical products and formulations jumped 3 percent in the day’s trade upon declaring record date for the bonus issue of 2:1. 

Price Action 

With a market capitalization of Rs. 66 Crores, the shares of JFL Lifesciences Limited were trading at Rs. 60 per equity share, up 3 percent from its previous day’s close price of Rs. 58.35. 

Bonus 

The Board of Directors of JFL Lifesciences Limited has announced issuing bonus equity shares of the company in the ratio of 2:1 where two equity shares of the firm with a face value of Rs. 10 will be issued to each equity share held as on the record date i.e., September 24, 2024. 

Also Read: EV stock jumps 3% after its 2 wheeler EVs receives Govt approval for EMPS scheme

About the company 

JFL Lifesciences Limited is engaged in the business of manufacturing, marketing, trading, and selling a wide range of pharmaceutical products and formulations across the global market. 

Its main product categories include dry powder injections, solid oral dosage forms, tablets and capsules, Oral rehydration solutions (ORS), beta-lactam dry powder injection products, and many others. 

Financials and Ratios 

Its revenue from operations grew by 8.69 percent from Rs. 42.83 Crores in FY23 to Rs. 46.55 Crores in FY24, accompanied by profits of Rs. 2.81 Crores to Rs. 3.31 Crores. 

Also Read: Ethanol stock jumps 5% after receiving order for supplying ethanol to BPCL, HPCL and IOCL

In terms of Return ratios, it has reported a return on equity (ROE) of 10.3 percent, and a return on capital employed (ROCE) of 11.8 percent. It has reported a debt-to-equity ratio of 0.16. 

Written by: Bharath K.S

Disclaimer

The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

×